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Abstract 
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia’s national drug subsidy program. This paper 
provides a practical guide to researchers using PBS data to examine prescribed medicine use.
Findings: Excerpts of the PBS data collection are available in a variety of formats. We describe the core components 
of four publicly available extracts (the Australian Statistics on Medicines, PBS statistics online, section 85 extract, under 
co‑payment extract). We also detail common analytical challenges and key issues regarding the interpretation of 
utilisation using the PBS collection and its various extracts.
Conclusions: Research using routinely collected data is increasing internationally. PBS data are a valuable resource 
for Australian pharmacoepidemiological and pharmaceutical policy research. A detailed knowledge of the PBS, the 
nuances of data capture, and the extracts available for research purposes are necessary to ensure robust methodol‑
ogy, interpretation, and translation of study findings into policy and practice.
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Findings
In recent decades the discipline of pharmacoepidemiol-
ogy has experienced exponential growth, both in Aus-
tralia [1] and internationally [2–4]. This growth has been 
driven, at least in part, by the increasing availability of 
routinely collected dispensing databases and increased 
access to data linkage of dispensing claims and other 
health data collections. In addition, there has been rec-
ognition of the limitations of randomised controlled tri-
als (RCTs) to inform post-market medicine use, including 
their short duration, small sample size, and non-repre-
sentative patient populations [5]. Studies using routinely 
collected databases overcome many of these difficulties, 
complementing findings from RCTs and offering valuable 
insights into the real-world use, safety, and effectiveness 
of medicines [2].
There are a wealth of databases available for pharma-
coepidemiological research, and while there are com-
monalities across health jurisdictions, each dataset has 
its own idiosyncrasies with respect to analysis and inter-
pretation. Researchers must be familiar with the limita-
tions and features of their chosen dataset. The purpose 
of this paper is to provide a practical guide for research-
ers using Australia’s Pharmaceutical Benefits Scheme 
(PBS) dispensing data. Specifically, we will set the scene 
by describing the PBS, the Australian Government’s sub-
sidised prescription medicines program. We will then 
detail the specifics of the PBS data collection and the PBS 
data extracts available to examine trends in prescribed 
medicine use. Finally, we will consider some of the fac-
tors affecting the interpretation of prescribed medicine 
use based on PBS claims.
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Background: the Pharmaceutical Benefits Scheme 
(PBS) and Repatriation Pharmaceutical Benefits 
Scheme (RPBS)
Australia has universal health care arrangements enti-
tling all citizens and permanent residents to a range of 
subsidised healthcare services. Prescription medicines 
are subsidised under two Commonwealth schemes: 
the PBS and the Repatriation Pharmaceutical Benefits 
Scheme (RPBS). The PBS subsidises prescribed medi-
cines for Australian residents and eligible foreign visitors 
(i.e. those with reciprocal health care agreements with 
Australia). The RPBS, available to eligible war veterans 
and their families, comprises all PBS-listed medicines 
and additional subsidised pharmaceutical items [6].
The Australian Government reimburses community 
pharmacies and private hospitals for PBS-listed medi-
cines, subsidising approximately 75  % of prescribed 
medicine use in Australia [7]. Prescriptions dispensed 
to public hospital inpatients have not traditionally been 
PBS-subsidised; however, the Australian Government 
has individual agreements with most Australian states 
and territories (except New South Wales and the Austral-
ian Capital Territory) under the Public Hospital Phar-
maceutical Reforms, enabling participating hospitals to 
provide discharging patients and outpatients with PBS-
subsidised medicines [8].
Schedule of Pharmaceutical Benefits
The PBS underpins Australia’s National Medicines Policy, 
which is concerned with providing access to safe, effec-
tive, and affordable medicines, and ensuring their quality 
use [9]. The PBS is governed by the National Health Act 
1953 and the National Health (Pharmaceutical Benefits) 
Regulations 1960 (Cth) Act, and is administered by the 
Department of Human Services (DHS; formerly known 
as Medicare Australia and the Health Insurance Com-
mission) under the Health Insurance Act 1973 (Cth).
A medicine is eligible for listing on the PBS or RPBS 
after it has been registered for use in Australia by the 
Therapeutic Goods Administration (TGA). To gain list-
ing it must be assessed and recommended by the Phar-
maceutical Benefits Advisory Committee (PBAC), an 
independent expert body appointed by the Australian 
Government. In making its recommendation, PBAC 
considers the medicine’s clinical place, effectiveness, 
safety, cost, and cost-effectiveness compared to currently 
available treatments [10]. After a positive recommenda-
tion from PBAC, the Minister for Health authorises the 
medicine to be listed on the Schedule of Pharmaceutical 
Benefits.
PBS benefit categories
Medicines are PBS-listed according to one of three ben-
efit categories [11]:
  • Unrestricted benefits Medicines available for general 
use without limits on the subsidised indication for 
prescribing.
  • Restricted benefits Medicines available for the treat-
ment of certain indications or patient groups. If the 
medicine is prescribed outside the PBS-specified 
indication, prescribers are required to write private 
(unsubsidised) prescriptions.
  • Authority required benefits An authority prescrip-
tion is required for certain restricted medicines 
and for cases where a higher dose or quantity 
of the medicine is required than the maximum 
approved on the PBS. Authority benefits fall into 
two categories: (a) Authority required prescrip-
tions, which require the prescriber to obtain 
written or telephone approval from DHS or 
Department of Veterans’ Affairs (DVA) before dis-
pensing is permitted; and (b) Authority required 
(STREAMLINED) prescriptions, which do not 
require prior approval from DHS or DVA, but a 
streamlined authority code must be provided on 
the prescription [12].
Sections of the Schedule of Pharmaceutical Benefits
Medicines listed on the Schedule of Pharmaceutical 
Benefits are also classified into sections based on the 
National Health Act 1953 [6, 13, 14].
  • Section  85 (s85) of the Act pertains to medicines 
available under the standard arrangements estab-
lished for medicine subsidy. S85 or general medi-
cines comprise the majority of prescriptions supplied 
under the PBS and RPBS.
  • Section  100 (s100) refers to medicines subsidised 
under special arrangements. For example, s100 medi-
cines may be restricted to supply through a hospital 
with specified specialist facilities [15]. This section 
includes many specialty, high cost medicines, such 
as chemotherapy and chronic illness agents, as well 
as medicine programs including the Botulinum Pro-
gram, Growth Hormone Program, In Vitro Fertilisa-
tion/Gamete Intrafallopian Transfer Program, and 
the Opiate Dependence Treatment Program [6, 14]. 
Special arrangements also exist for the supply of PBS 
medicines to clients of eligible Aboriginal Health 
Services in remote areas of Australia [16].
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Patient categories
Beneficiary status
To ensure affordability of medicines for all Austral-
ians, the level of subsidy under the PBS depends on the 
patient’s beneficiary status. Concessional status was estab-
lished for individuals who are eligible to receive govern-
ment entitlements, including pensioners, low-income 
earners, repatriates, and Indigenous Australians living 
with or at risk of chronic illness (the latter under the Clos-
ing the Gap co-payment measure) [17, 18]. Eligible veter-
ans and their dependents holding a DVA health card are 
also entitled to medicines and additional pharmaceutical 
items at concessional rates under the RPBS [19]. These 
patients have a low co-payment threshold. All other indi-
viduals are considered general beneficiaries and have a 
higher co-payment threshold. As of 1 January 2015, the 
maximum co-payment was AUD$6.10 for concessional 
beneficiaries and AUD$37.70 for general beneficiaries 
[20]. For medicines costing more than the relevant benefi-
ciary co-payment (i.e. over co-payment), additional costs 
are paid by the Commonwealth. Medicines costing less 
than the relevant co-payment (i.e. under co-payment) are 
not subsidised, but paid in full by the patient. Currently 
all PBS-listed medicines are priced above the concessional 
beneficiary co-payment but may be priced above or below 
the general beneficiary co-payment.
PBS Safety Net
The PBS Safety Net was established to provide financial 
assistance to individuals and their families spending large 
amounts on medicines in a calendar year. Once a fam-
ily collectively spends over the threshold amount (as of 
1 January 2015, AUD $1453.90 for general beneficiar-
ies and AUD $366.00 for concessional beneficiaries), the 
subsequent cost of dispensings for all family members 
are reduced such that general beneficiaries pay the con-
cessional co-payment rate, and concessional beneficiar-
ies have no co-payments so they receive medicines free 
of charge [20]. As the reduced cost of dispensings can 
encourage patients to obtain additional quantities of 
medicines before they are needed, the Government 
introduced the Safety Net 20 day rule on 1 January 2006 
to encourage responsible use of the PBS. The rule means 
that, for selected PBS-subsidised medicines used for 
long-term therapy, a repeat supply of the same medicine 
within 20 days does not count towards reaching the PBS 
Safety Net threshold. Moreover, these medicines will 
not be supplied at the reduced price if the threshold has 
already been reached [21].
Doctor/prescriber bag (emergency drug supply)
Certain PBS medicines are provided to doctors to treat 
patients in emergencies [22]. These medicines are free for 
the doctor and patient as they are completely subsidised 
by the Commonwealth.
The PBS/RPBS data collection
PBS/RPBS dispensing claims submitted for payment of a 
government subsidy are processed by DHS and provided 
to the Department of Health (DoH) and DVA (for their 
clients only) for monitoring, evaluation, and health ser-
vice planning.
As of 1 April 2012, DHS also processed dispensing 
records for under co-payment medicines. The collection 
of under co-payment records was agreed to under the 
Fifth Community Pharmacy Agreement and legislated 
under the National Health Amendment (PBS) Act 2010 
[23]. As a result, under co-payment dispensing data are 
now recorded in the PBS data collection.
When a PBS/RPBS medicine is dispensed, the admin-
istering pharmacy or hospital provides DHS with data 
pertaining to the prescription dispensed, identity of the 
patient, prescribing doctor, and supplying pharmacy. 
This information forms the basis of the PBS collection. 
Identifying information about the patient, doctor and 
pharmacy (such as names and addresses) is not available 
to researchers or in the public domain. Moreover, poli-
cies such as the suppression of cell counts in aggregated 
public domain data also apply to protect patient privacy. 
A summary of key variables provided in the PBS collec-
tion is provided in Table 1.
Details of medicine dispensings requiring written or 
telephone authorisation are stored in a separate Author-
ity Approvals database by DHS. This database records 
prescription details for authority required medicines, 
including patient identifiers, PBS item code, the date on 
which authority approval was obtained, prescriber iden-
tifiers, and the authority restriction number, which pro-
vides the reason, or indication, for dispensing as declared 
by the prescribing physician. However, the validity of 
authority codes (including streamlined) for inferring 
patient diagnosis is uncertain; this relies on the doctor or 
pharmacist selecting the correct code.
PBS/RPBS data extracts
PBS/RPBS data are available in a variety of formats. 
Aggregated (de-identified) data are available online from 
DHS [24] or DoH [25] in fixed or interactive forms, while 
more detailed, customised reports in aggregated or unit-
record formats can be requested from DHS, DoH, or 
DVA.
Publicly available data
Australian Statistics on Medicines (ASM) The ASM 
reports are produced annually by the Drug Utilisation 
Sub-Committee (DUSC) of the PBAC for the purpose of 
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estimating total community use of prescription medicines 
based on volume, defined daily dose (DDD) per 1000 
population per day (DDD/1000 pop/day), and government 
and patient costs [26]. The DUSC database, which is the 
source of the ASM reports, combines the PBS/RPBS data-
set with estimates of non-subsidised (under co-payment 
and private) prescription medicines use obtained from an 
ongoing Pharmacy Guild Survey of approximately 370 
community pharmacies. However, the Pharmacy Guild 
Survey ceased on 1 August 2012 with the establishment 
of the Fifth Community Pharmacy Agreement and sub-
sequent collection of under co-payment dispensings by 
DHS. ASM reports are presented according to PBS item 
and Anatomical Therapeutic Chemical (ATC) codes, 
aggregated by year of dispensing and according to the 
recording source (PBS/RPBS or Pharmacy Guild Survey). 
The ASM is available in print from 1991 to 1996, and 
online from 1997 [26].
Table 1 Core variables present in the PBS data collection. Availability to researchers depends on the data extract
ATC Anatomical Therapeutic Chemical, DDD/1000 pop/day defined daily dose per 1000 population per day, DHS Department of Human Services, WHO World Health 
Organisation
a ATC codes provided in the PBS dataset may occasionally differ from those determined by WHO
Variable Definition
Medicine details
 ATC code Internationally accepted, WHO‑defined codesa that classify medicines over five levels, starting broadly with the ana‑
tomical site of action (e.g. nervous system) and ending specifically with the chemical substance (e.g. oxycodone) 
[44]
 PBS item code Pharmaceutical Benefits Scheme defined codes that provide medicine details at the product level, including generic 
name, form, strength, administration route, quantity per unit (pack size), and approved indication, where applicable
 Medicine section Classification according to section of the PBS Schedule (section 85 or 100)
Prescription details
 Date of prescription Date on which the prescription was written
 Date of supply Date on which the medicine was supplied/dispensed by the pharmacy or hospital
 Date of processing Date on which the claim was processed by DHS
 Prescription type Describes whether the prescription is an original, repeat, deferred supply, authority, etc
 Total cost The gross price of the prescription, including the patient contribution plus the net benefit
 Patient contribution The amount paid by the patient for the prescription
 Government contribution The benefit paid to the pharmacy by the Australian Government
 Prescription category The program under which the prescription was dispensed (e.g. PBS, RPBS, under co‑payment, private etc.)
 Regulation 24 status Indicates that the original supply and all repeats were dispensed at once
 Streamlined authority code Indicates the physician‑declared indication or reason for prescription for Authority required (STREAMLINED) medicines
Patient details
 Patient identifier A unique, scrambled patient identifier provided by the Australian Government, allowing derivation of additional 
patient characteristics such as age (via date of birth), sex and geographical location
 Patient category The beneficiary status of the patient (e.g. concessional, general, safety net, doctor’s bag, under co‑payment, Closing 
the Gap); determines how much the patient contributes to their medicine cost
 Patient location The location (e.g. state, statistical local area) of the patient
Measures of utilisation
 Quantity The quantity of medicine supplied to the patient
 Number of dispensings/
scripts
The number of prescriptions dispensed (including original and repeat)
 DDD/1000 pop/day A measure of utilisation based around the WHO Defined Daily Dose (DDD), allowing for standardisation of use across 
different countries and drug formulations; provides a rough estimate of the proportion of the population treated 
daily with the medicine of interest [45]
Prescriber information
 Prescriber identifier A unique, scrambled number identifying the prescribing doctor
 Prescriber specialty Identifies the specialty of the prescribing doctor (e.g. general practitioner, psychiatrist etc.)
 Prescriber location The location (e.g. state, statistical local area) of the prescribing doctor
Pharmacy information
 Pharmacy identifier A unique, scrambled number identifying the dispensing pharmacy
 Pharmacy location The location (e.g. state) of the dispensing pharmacy
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Medicare Australia PBS item and  group reports (here‑
after PBS Statistics online) DHS has developed online, 
interactive reports detailing aggregated PBS and RPBS 
dispensing volume and costs to government [24]. The cus-
tomised reports, available from 1992, can be downloaded 
based on individual PBS item codes, or grouped by ATC 
classifications (e.g. alimentary tract and metabolism) or 
patient category. Reports can also be formatted according 
to the state/territory location of the dispensing pharmacy, 
and according to month, calendar year or financial year of 
processing. Importantly, the reports do not include data 
on under co-payment or private prescriptions and there 
is limited capture of s100 medicines [27]. Data on s100 
highly specialised drugs dispensed in public hospitals 
are not available prior to July 2013; a transition to online 
claiming in public hospitals enabled collection of data at 
the level of the individual prescription from this date [28]. 
Reports are based on date of processing by DHS, not the 
date of supply.
Section 85 extract DoH has developed an online, down-
loadable extract of s85 dispensing records [25]. Reports 
are available by month of processing (annually from 
2008/2009, with monthly updates), or month of sup-
ply (single extract from July 2009, excluding most recent 
6  months). Both reports aggregate volume and costs 
according to patient category. These data also include 
under co-payment medicines from 1 July 2012 and Clos-
ing the Gap under co-payment data from 1 July 2010.
PBS/RPBS under co‑payment extract An online, down-
loadable extract of PBS/RPBS under co-payment data 
was made available by DoH in July 2012 [29]. The extract 
is based on date of processing and aggregates volume 
by month, according to patient category, scheme (PBS, 
RPBS), and schedule (s85 or s100).
Data available on request
DHS, DoH, and DVA have mechanisms in place for 
researchers to request PBS/RPBS reports in aggregated 
or unit-record format to address specific research ques-
tions. Customised extracts of the DUSC database can 
be requested from the PBS Information Management 
Section, Pharmaceutical Policy Branch, Department of 
Health, and are provided in aggregated (de-identified 
form) from 1987, incorporating the Pharmacy Guild 
Survey from 1989 to August 2012. After this period the 
DUSC database extracts incorporate PBS/RPBS and 
under co-payment dispensings. These extracts have the 
advantage of more complete medicines capture than the 
PBS/RPBS databases alone. Another PBS extract worth 
mentioning is the PBS 10 % sample, a standardised, longi-
tudinal, unit-record extract containing all PBS medicine 
dispensing data for a random 10 % sample of Australians. 
Access is established via a contract with DHS. Research-
ers can also obtain access to a Fact of Death Data (FODD) 
file from DHS. This file is compiled by the Australian 
Institute of Health and Welfare using monthly data from 
state and territory registries of births, deaths and mar-
riages, and is matched to PBS/RPBS dispensing records 
[30]. All other data extracts require specific approval.
The main features of the data extracts in this section 
are described in Table 2.
Factors affecting the interpretation of prescribed 
medicine use based on PBS/RPBS claims
This section describes some of the common challenges 
encountered when using the PBS/RPBS database and its 
various extracts to obtain utilisation estimates.
Seasonality
PBS data are subject to seasonality due to the effect of the 
Safety Net (Fig. 1). As previously mentioned, when a fam-
ily spends over a specified amount on PBS medicines in 
one calendar year (i.e. exceeds the Safety Net threshold), 
the cost of all subsequent PBS medicines are reduced to 
the concessional rate for general beneficiaries and are 
free for concessional beneficiaries. This reduced medi-
cine price on reaching the Safety Net can lead to a phe-
nomenon known as stockpiling: Safety Net entitlements 
result in some patients obtaining extra quantities of their 
medicines toward the end of the year, stockpiling for 
the new year when they revert back to paying standard 
prices. This results in increased rates of dispensing of the 
medicine toward the end of the year followed by a trough 
at the start of the next year. Despite attempts to reduce 
this phenomenon through the introduction of the Safety 
Net 20 day rule on 1 January 2006, stockpiling continues 
to result in pronounced seasonality in utilisation data 
based on date of supply.
Date of supply vs. date of processing
Each dispensing claim records the date a medicine is 
supplied to a patient by the dispensing pharmacy or the 
date the dispensing pharmacy’s claim for reimburse-
ment is processed by DHS. Some of the data extracts 
include both of these variables while others include only 
one. For example, ASM reports are based around date of 
supply, PBS Statistics online use date of processing, and 
Section  85 online extracts are available by either date. 
There is often a discrepancy in utilisation measures based 
on date of supply versus those based on date of process-
ing as the processing of the claim occurs some time after 
the prescription is dispensed and the interval of time 
between dispensing and processing is variable [25]. As 
such, caution must be employed when using data based 
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Table 2 Comparison of data extracts: information available to researchers
ASM DUSC PBS Statistics online PBS Section 85 Under co-payment PBS 10 % sample
Access
 Online ✓ ✓ ✓ ✓
 By request ✓ ✓
 Data custodian DoH DoH DHS DoH DoH DHS
 Access fee ✓ ✓
Level of record
 Aggregate ✓ ✓ ✓ ✓ ✓
 Unit‑level ✓
Date of record
 Date of processing ✓ ✓ ✓ ✓
 Date of supply ✓ ✓ ✓ ✓
 Date of prescription From Sep 2012
Time
 Data available (start–end) 1991–2011 1987–present 1992–present 2009–present 2012–present 2005–present
 Measurement unita Year Month Month Month Month Day
 Frequency of updates Calendar year By request Month Month Financial year Quarter
Patient information
 Scrambled identifier ✓
 Agea 5 year age groupsb From year of birth
 Sex ✓b ✓
 Geographical areaa National Stateb State National National National
 Fact of death Year of death
Prescriber information
 Scrambled identifier ✓
 Specialty ✓b ✓
Pharmacy information
 Geographical location State State
Medicine classification
 ATC code ✓ ✓ Highest level only ✓
 PBS item code ✓ ✓ ✓ ✓ 2012–2013 report only ✓
Patient category
 General beneficiary ✓b ✓ ✓ 2012–2013 report only ✓
 Concessional beneficiary ✓b ✓ ✓ 2012–2013 report only ✓
 Repatriation beneficiary ✓b ✓ ✓ 2012–2013 report only
 ‘Closing the Gap’ ✓b ✓
 Doctor’s bag ✓b ✓ ✓ ✓
PBS dispensing data capture
 PBS ✓ ✓ ✓ ✓ 2013–2014 report only ✓
 RPBS ✓ ✓ ✓ ✓ 2013–2014 report only
Additional dispensing capture
 Under co‑payment  
dispensing
From 1989 From 1989 From 2012 From 2012
 Private dispensing 1989–2011 1989–2012
Medicine sections
 Section 85 ✓ ✓ ✓ ✓ ✓ ✓
 Section 100 Limited Limited Limited ✓ ✓
Measures
 Volume (no. of dispensing 
records)
✓ ✓ ✓ ✓ ✓ ✓
 DDD/1000 population/day ✓ ✓
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around date of processing, particularly when examining 
medicine use at particular time points; these figures are 
primarily useful for obtaining rough approximations of 
utilisation. Date of supply should be used preferentially 
for examining medicine use.
Figure  2 depicts the discrepancy between utilisation 
estimates based on date of supply compared to date of 
processing for all s85 PBS-subsidised medicines. Troughs 
in utilisation according to date of processing can be seen 
around late 2011 and late 2013, indicating delays in  the 
processing of claims by DHS. The 2011 trough is followed 
by compensatory peaks, indicating a period of increased 
processing. Note that the data by date of supply show sea-
sonal fluctuations as mentioned above. Seasonal fluctua-
tions are less apparent in date of processing graphs due 
to the variable delay between dispensing and processing.
The risks of using date of processing data are well dem-
onstrated by a recent example. In October 2013, the 
Australian Broadcasting Corporation’s Catalyst program 
aired a two part series questioning the link between high 
cholesterol levels and heart disease and suggested that 
the benefit of statins for preventing cardiovascular dis-
ease had been exaggerated. Much public debate followed 
the program. In May 2014, Australian Doctor published 
an article based on PBS statistics online data, reporting 
that there had been no change in statin dispensing for 
up to 3  months after the program aired [31]. However, 
our interrupted time series analysis using date of supply 
showed that there was an immediate and sustained 2.6 % 
reduction (equating to 500,000 fewer prescriptions) in 
statin dispensing persisting up to 8 months after the pro-
gram aired [32].
One caveat concerning use of date of supply data is 
that dispensing records are not available in the dataset 
until the claim has been processed by DHS. Due to the 
variable delay in processing, this can result in incomplete 
ascertainment of claims dispensed on a given date for a 
number of months. It is therefore advisable to truncate 
the observation end date by at least 3 months, and pref-
erably 6 months, to avoid under-reporting of utilisation. 
Indeed, the Section  85 Date of Supply report does not 
contain data for the most recent 6 months to ensure that 
Information accurate as of 1 July 2015
ASM Australian Statistics on Medicines, ATC Anatomical Therapeutic Chemical, DHS Department of Human Services, DoH Department of Health, DUSC Drug Utilisation 
Sub-Committee, PBS Pharmaceutical Benefits Scheme, RPBS Repatriation Pharmaceutical Benefits Scheme
a Smallest unit available
b Available for PBS/RPBS data only
Table 2 continued
ASM DUSC PBS Statistics online PBS Section 85 Under co-payment PBS 10 % sample
 Cost to patient ✓b ✓
 Cost to government ✓b ✓ ✓
 Total cost (patient + govern‑
ment)
✓ ✓b ✓
Fig. 1 The seasonality effect of dispensing records. Monthly dispensings of proton pump inhibitors to concessional beneficiaries, January 2010 to 
January 2014. Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme Section 85 Supply data, Australian Government 
Department of Health [25]
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the data are of a satisfactory level of completion before 
publication.
Ascertainment and under co-payment medicines capture
As previously mentioned, the PBS database did not cap-
ture data on the dispensing of under co-payment medi-
cines until at least April 2012 (July 2012 for Section  85 
Date of Supply), thereby under-ascertaining the utilisa-
tion of certain medicines prior to this time. As under co-
payment prescriptions comprised approximately 18 % of 
medicine use in 2011 [7], this issue significantly impacts 
utilisation estimates for certain drugs.
To determine if a particular PBS item was under-
ascertained it is necessary to track the time points at 
which the cost of the medicine fell below the general 
co-payment threshold in the study period (prior to April 
2012). As the co-payment threshold increases yearly and 
medicine prices change over time, the medicine’s price 
must be compared to the yearly co-payment threshold 
throughout the period of interest. The inclusion of under 
co-payment data in 2012 also must be considered when 
examining utilisation of under co-payment medicines 
over this period. It should also be noted that while DHS 
now records all under co-payment dispensing claims, not 
all of the collections detailed in this document incorpo-
rate under co-payment data as part of the extract (see 
Table 2).
An example of how these issues affect the data is pro-
vided in Fig.  3. Oxycodone suppositories (30  mg; PBS 
item code 2481N) were under co-payment between Jan-
uary 1998 and December 2004. Oxycodone utilisation 
was under-ascertained in the PBS dataset for the dura-
tion of this under co-payment period; only use by con-
cessional beneficiaries or general beneficiaries qualifying 
for the PBS Safety Net were captured. In December 2004, 
the price of item 2481N increased from AUD$18.42 to 
AUD$29.84, exceeding the co-payment threshold of 
AUD$23.70. This transition to over co-payment resulted 
in more complete capture of medicine use; PBS-subsi-
dised utilisation increased as a result, and under co-pay-
ment utilisation dropped off. As this medicine was above 
co-payment in 2012, it was not affected by the change in 
data collection by DHS.
However, the impact of this change on medicine ascer-
tainment can be demonstrated by examining trends in 
antidepressant utilisation over this period. As many anti-
depressants are off-patent, there is a high rate of under 
co-payment utilisation of this class. Accordingly, Fig.  4 
demonstrates a sharp increase in antidepressant pre-
scriptions coinciding with the uptake of under co-pay-
ment medicines into the dataset.
The capture of under co-payment medicines has impli-
cations for analyses using unit-level data. If the medicine 
of interest is under co-payment for all or part of the study 
period, restriction of the study population to conces-
sional beneficiaries or DVA clients can ensure more com-
plete ascertainment of medicine use. This is because the 
concessional co-payment threshold is lower than the cost 
of any medicine on the PBS.
This method has been widely used in Australian studies 
using unit-level PBS data: of 113 such studies published 
between 1987 and 2013, 75 % employed a study popula-
tion comprised of concessional beneficiaries or veterans 
[1]. As the concessional status of a patient can change 
over time, inclusion should ideally be further restricted 
to individuals for whom all dispensed medicines are pro-
vided at the concessional rate during the study period. 
Alternatively, under co-payment use of medicines 
Fig. 2 Number of dispensings by date of supply and date of processing. Monthly number of dispensings for all section 85 PBS‑subsidised medi‑
cines January 2010 to January 2014, represented by date of supply and date of processing. Pharmaceutical Benefits Scheme and Repatriation 
Pharmaceutical Benefits Scheme Section 85 Supply and Processing Data, Australian Government Department of Health [25]
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requiring written or telephone authority approval can be 
tracked using the Authority Approvals database (such as 
use of dexamphetamine and methylphenidate in atten-
tion deficit hyperactivity disorder).
Changes to medicine coding: ATC and PBS item code 
changes
Both PBS item and ATC codes are subject to change and 
this requires consideration when examining utilisation 
trends. For example, the antidepressant venlafaxine was 
listed under the ATC code N06AE06 until 1995, when 
its code changed to N06AA22. The code was further 
changed in 1999 to N06AX16 [33]. Similarly, a particu-
lar formulation of tobramycin, a systemic antibiotic, had 
the PBS item code 1356J until December 2005, when the 
code changed to 8872Y [34]. While the original item code 
still exists, it no longer refers to this formulation.
It is therefore important to ensure that all relevant 
historical and current ATC and/or PBS item codes are 
included in the analysis to avoid errors in utilisation 
estimates. Defining medicines of interest by ATC codes 
rather than item codes can help to overcome this problem, 
as ATC codes capture all current and historical PBS item 
codes, are less prone to change, and any historical changes 
in ATC code can be easily determined from the World 
Health Organisation Collaborating Centre for Drug Statis-
tics Methodology (WHOCC) website [33]. One caveat is 
that there are occasional differences between the WHO-
defined ATC codes and the ATC codes present in the PBS 
dataset. For example, lithium carbonate is classified as an 
antipsychotic by WHO (code N05AN01) but as an antide-
pressant by the PBS (code N06AX) [35]. Changes in PBS 
item codes are more difficult to track, but are recorded 
from 2003 in PBS monthly reports [36].
Fig. 3 The effect of co‑payment status on utilisation estimates, by script type. Yearly number of dispensings of oxycodone suppositories (30 mg; 
PBS item code 2481 N), 1998–2013. The co‑payment status of the medicine is indicated. Note that measures of utilisation using PBS/RPBS prescrip‑
tions under‑estimate total use when the medicine is under co‑payment. Drug Utilisation Sub‑Committee combined dataset, Australian Govern‑
ment Department of Health
Fig. 4 Utilisation of antidepressants increases in July 2012 with the addition of under co‑payment data to the PBS dataset. Pharmaceutical Benefits 
Scheme and Repatriation Pharmaceutical Benefits Scheme Section 85 Supply data, Australian Government Department of Health [25]
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It is also worth noting that a medicine may concur-
rently have more than one ATC code (when the medicine 
has multiple indications affecting different body systems) 
or item code [according to the indication, strength, or 
prescriber (i.e. medical practitioner, nurse practitioner, 
or dentist) of a particular formulation]. Therefore, in 
some cases, the item code may provide a proxy of the 
indication or reason for prescribing. For example, the 
antineoplastic bevacizumab is available under item code 
10114H for epithelial ovarian, fallopian tube or primary 
peritoneal cancer, but under 4400N for colorectal can-
cer. However, other drugs have multiple indications for 
prescribing combined under a single code (e.g. one item 
code for the antidepressant paroxetine is used for major 
depressive disorder, obsessive compulsive disorder, and 
panic disorder). Additionally, the validity of item codes 
for inferring patient diagnosis is uncertain. Depending 
on the research question, the researcher may choose to 
include all codes or only those referring to a certain indi-
cation or prescriber type.
Policy changes
Changes in the medicine reimbursement process can 
impact data capture and estimates of utilisation. For 
example, the introduction of the Public Hospital Phar-
maceutical Reforms from 2001 increased access to PBS-
subsidised medicines by allowing participating public 
hospitals to provide PBS medicines to patients at dis-
charge and outpatients. These Reforms are governed by 
individual agreements between each state and territory 
and the Australian Government. Agreements were ini-
tially established in Victoria (September 2001), followed 
by Queensland (August 2002), Western Australia (2002), 
Northern Territory (January 2007), South Australia 
(August 2008) and Tasmania (December 2010), with 
reforms implemented gradually across each state [37]. 
New South Wales and the Australian Capital Territory 
do not participate in the Reforms. Researchers conduct-
ing state-by-state comparisons should consider whether 
the introduction of the Reforms may influence utilisation 
estimates for the medicines of interest. A variable indi-
cating the type of dispensing pharmacy (hospital, com-
munity) can be provided with PBS data by request.
In late 2011 the Pharmaceutical Reforms were var-
ied to enable the introduction of a new scheme govern-
ing the subsidy of chemotherapeutic agents, the Revised 
Arrangements for the Efficient Funding of Chemo-
therapy measure [37]. These arrangements came into 
effect in December 2011 for private hospitals and com-
munity pharmacies, and April 2012 for public hospi-
tals [38]. S100 medicines dispensed in public hospitals 
have traditionally been processed in bulk by DHS at the 
end of each month, and therefore were not recorded as 
individual-level dispensing claims or included in the 
dataset. However, the Efficient Funding of Chemotherapy 
resulted in a shift from bulk to unit-level processing of 
s100 chemotherapeutic items and increased capture of 
these medicines in the dataset. As such, an increase in 
utilisation of s100 medicines dispensed through public 
hospitals can be observed following the introduction of 
the scheme. These examples highlight the need to ques-
tion significant and unexpected changes in the data to 
determine whether they represent a true change in uti-
lisation or an artefact of the way the data are ascertained.
Measures of utilisation
Medicine use can be quantified in a variety of ways in the 
PBS dataset, including by number of dispensings or costs. 
The strength of the medicine and quantity supplied can 
also be used to calculate DDD/1000 pop/day, a widely 
used measure of utilisation allowing for standardisation 
of drug use across countries and different forms of the 
drug. The DDD metric, established by the WHOCC, is 
based on the estimated mean daily dose of the drug when 
used for its main indication in adults [6]. DDD/1000 pop/
day can be calculated for both plain products (which con-
tain only one active ingredient) and combination prod-
ucts (with more than one active ingredient). The DUSC 
calculates DDD/1000 pop/day for combination products 
by counting the DDD for each constituent separately [7]; 
this method contrasts  with that used by the WHOCC, 
who assign DDDs by counting the entire combination 
as one daily dose [39]. This methodological difference 
should be considered when making international com-
parisons of utilisation using DDDs.
Different measures of utilisation may yield differ-
ing results, and researchers must determine which 
measure(s) is most appropriate for their research ques-
tion and dataset, considering the strengths and limi-
tations of the chosen measure. Prescription-based 
measures such as ‘number of dispensings’ do not stand-
ardise utilisation across populations, or across different 
medicine strengths and pack sizes. While DDD/1000 
pop/day is useful for standardising population-based 
measurements, the DDD on which it is based does not 
necessarily accurately reflect the dose recommended or 
prescribed. DDD is also limited for quantifying medi-
cines use in children and the elderly, for whom differ-
ent doses may be used. As with ATC codes, DDDs can 
change over time; a list of changes can be accessed from 
WHOCC [40].
Figure  5 demonstrates the differing results obtained 
when measuring utilisation by number of prescriptions 
dispensed, DDD/1000 pop/day, or medicine cost to gov-
ernment for the antipsychotic quetiapine; the antidepres-
sant desvenlafaxine; the benzodiazepine diazepam; and 
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the stimulant methylphenidate. Each of these measures 
have certain strengths and weaknesses. For example, the 
DDD of quetiapine is 400 mg, which is the average dose 
for an adult patient diagnosed with psychosis. However, 
a recent analysis by DUSC revealed that 23 % of patients 
taking quetiapine are using only the 25 mg strength of the 
drug, likely for the treatment of non-psychotic disorders 
such as anxiety and insomnia [41]; DDD/1000 pop/day 
would therefore likely under-estimate true use. In addi-
tion, quetiapine is one of the most costly medicines to the 
Australian Government [42], and analyses relying solely 
on cost would over-estimate its utilisation. Assessment of 
utilisation by number of prescriptions dispensed can also 
be problematic when comparing between different drugs, 
strengths and pack sizes. Quetiapine, for example, is usu-
ally dispensed in packs of 60 tablets, while desvenlafaxine 
has a pack size of 28. Use of different measures of utilisa-
tion may also impact trends in medicine use. For example, 
the increase in quetiapine use between 2006 and 2011 is 
more pronounced when measured by number of prescrip-
tions (232  % increase) than by cost (154  % increase) or 
DDD/1000 pop/day (123 % increase).
Conclusions
As a result of its universal healthcare arrangements, Aus-
tralia has access to a whole-of-population dispensing 
database. The PBS data collection contains records on 
Australia’s 23 million citizens and all PBS, RPBS and 
under co-payment prescriptions, amounting to approxi-
mately 280 million dispensings a year [42]. The data-
base is a valuable resource and has been widely used in 
both aggregated and unit-level analyses, and in linked 
and unlinked forms. The current paper has provided an 
overview of the PBS database and some of the extracts 
available to researchers, focussing primarily on publicly 
available, aggregated forms. Clearly these extracts hold 
great potential as a continuing source of data for phar-
macoepidemiological research in Australia. However, the 
scope of the PBS database extends beyond the extracts 
and uses described herein.
We recently published a systematic review of all pub-
lished literature using Australia’s PBS dispensing records 
between 1987 and 2013, identifying 228 studies using 
PBS data [1]. These studies explored a range of research 
questions, including trends in drug utilisation; clinical 
and patient practices around medicine use; drug use and 
outcomes; evaluations of interventions; and methodo-
logical studies undertaken using PBS claims. They also 
used a variety of PBS data extracts, including the publicly 
available Section  85 extract and PBS Statistics online, 
as well as a range of datasets available by request, such 
as the DUSC dataset, PBS 10 % sample, and DVA RPBS 
dataset. More than half of the studies combined PBS 
data with additional health data such as medical service 
claims—also under the custodianship of DHS—or other 
routine data such as hospitalisations, fact and cause of 
death data under the custodianship of Australia’s states 
and territories. Sixty-three studies linked person-level 
claims with other routine data collections, permitting 
exploration of drug safety and outcomes and the evalu-
ation of the impact of interventions on utilisation. While 
the availability of linked data in Australia has tradition-
ally been limited by legislative, privacy and cross-juris-
dictional barriers, recent developments in data linkage 
infrastructure and governance in Australia bring the 
promise of increased access to population-based linked 
data for research purposes [43]. These developments, 
combined with the recent changes in data capture, such 
as the inclusion of under co-payment data in the PBS 
dataset from 2012, further strengthen the role of the PBS 
dataset in pharmacoepidemiological research and place 
Australia in a powerful position to conduct quality use of 
medicines research.
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